000650 仁和药业
交易中 07-17 09:57:45
资讯
新帖
简况
股市必读：仁和药业（000650）7月13日董秘有最新回复
证券之星 · 07-14
股市必读：仁和药业（000650）7月13日董秘有最新回复
仁和药业：截至2026年7月10日，大约8.91万户左右
证券之星 · 07-13
仁和药业：截至2026年7月10日，大约8.91万户左右
仁和药业：目前只有ULOOK眼镜合作项目
证券之星 · 07-09
仁和药业：目前只有ULOOK眼镜合作项目
股市必读：仁和药业（000650）7月7日董秘有最新回复
证券之星 · 07-08
股市必读：仁和药业（000650）7月7日董秘有最新回复
股市必读：仁和药业（000650）7月3日董秘有最新回复
证券之星 · 07-06
股市必读：仁和药业（000650）7月3日董秘有最新回复
股市必读：仁和药业（000650）7月1日董秘有最新回复
证券之星 · 07-02
股市必读：仁和药业（000650）7月1日董秘有最新回复
仁和药业：二冬汤颗粒在通过初步形式审查的目录外药品名单-基本目录（序号81）
证券之星 · 07-01
仁和药业：二冬汤颗粒在通过初步形式审查的目录外药品名单-基本目录（序号81）
仁和药业（000650）披露2025年年度股东会决议公告，6月26日股价下跌2.73%
证券之星 · 06-26
仁和药业（000650）披露2025年年度股东会决议公告，6月26日股价下跌2.73%
股市必读：仁和药业（000650）6月24日董秘有最新回复
证券之星 · 06-25
股市必读：仁和药业（000650）6月24日董秘有最新回复
仁和药业：引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径
证券之星 · 06-24
仁和药业：引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径
仁和药业（000650）披露全资子公司获得清肺汤颗粒药品注册证书的公告，6月22日股价上涨0.39%
证券之星 · 06-22
仁和药业（000650）披露全资子公司获得清肺汤颗粒药品注册证书的公告，6月22日股价上涨0.39%
每周股票复盘：仁和药业（000650）实控人变更为杨潇，奥司他韦获批
证券之星 · 06-21
每周股票复盘：仁和药业（000650）实控人变更为杨潇，奥司他韦获批
仁和药业（000650）披露子公司获得磷酸奥司他韦干混悬剂药品注册证书，6月16日股价下跌1.31%
证券之星 · 06-16
仁和药业（000650）披露子公司获得磷酸奥司他韦干混悬剂药品注册证书，6月16日股价下跌1.31%
仁和药业：已获批件的产品公司都有生产和销售
证券之星 · 06-16
仁和药业：已获批件的产品公司都有生产和销售
股市必读：仁和药业（000650）6月15日董秘有最新回复
证券之星 · 06-16
股市必读：仁和药业（000650）6月15日董秘有最新回复
仁和药业：截至2026年5月29日，大约9.02万户左右
证券之星 · 06-12
仁和药业：截至2026年5月29日，大约9.02万户左右
仁和药业：截止2026年5月31号，公司的员工人数4805人
证券之星 · 06-10
仁和药业：截止2026年5月31号，公司的员工人数4805人
仁和药业：深圳三浦公司还需在原料、精准功效、技术壁垒和产品差异化等方面下苦功
证券之星 · 06-09
仁和药业：深圳三浦公司还需在原料、精准功效、技术壁垒和产品差异化等方面下苦功
仁和药业（000650）披露股份回购进展公告，6月1日股价上涨1.5%
证券之星 · 06-01
仁和药业（000650）披露股份回购进展公告，6月1日股价上涨1.5%
股市必读：仁和药业（000650）5月25日董秘有最新回复
证券之星 · 05-26
股市必读：仁和药业（000650）5月25日董秘有最新回复
公司概况
公司名称：
仁和药业股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-10
主营业务：
仁和药业股份有限公司的主营业务是药品及大健康产品的生产和销售。公司的主要产品是口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂、健康相关产品。
发行价格：
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":5.5,"timestamp":1784253465000,"preClose":5.51,"halted":0,"volume":12602400,"delay":0,"changeRate":-0.0018,"floatShares":1331000000,"shares":1400000000,"eps":0.2638,"marketStatus":"交易中","change":-0.01,"latestTime":"07-17 09:57:45","open":5.53,"high":5.6,"low":5.46,"amount":69845200,"amplitude":0.0254,"askPrice":5.51,"askSize":841,"bidPrice":5.5,"bidSize":257,"shortable":0,"etf":0,"ttmEps":0.2638,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784259000000},"marketStatusCode":2,"adr":0,"adjPreClose":5.51,"symbolType":"stock","openAndCloseTimeList":[[1784251800000,1784259000000],[1784264400000,1784271600000]],"highLimit":6.06,"lowLimit":4.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"isCdr":false,"pbRate":1.23,"roa":"--","peRate":20.849128,"roe":"2.2%","epsLYR":0.28,"committee":-0.269246,"marketValue":7700000000,"turnoverRate":0.0095,"status":1,"floatMarketCap":7323000000},"requestUrl":"/m/hq/s/000650/wiki","defaultTab":"wiki","newsList":[{"id":"2651314681","title":"股市必读：仁和药业（000650）7月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651314681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651314681?lang=zh_cn&edition=full","pubTime":"2026-07-14 01:44","pubTimestamp":1783964653,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，仁和药业报收于5.37元，上涨2.09%，换手率2.2%，成交量29.34万手，成交额1.58亿元。董秘最新回复投资者： 你好！公司暂无应披露而未披露的信息，请关注公司后续公告。敬请发布7月上旬末公司股东户数信息。董秘： 谢谢您的关注，截至2026年7月10日，大约8.91万户左右。当日关注点交易信息汇总：7月13日主力资金净流出514.74万元，游资资金净流出593.22万元，散户资金净流入1107.96万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400001323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","000650","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651192735","title":"仁和药业：截至2026年7月10日，大约8.91万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2651192735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651192735?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:57","pubTimestamp":1783933026,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)07月13日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布7月上旬末公司股东户数信息。谢谢！致礼！仁和药业回复：谢谢您的关注，截至2026年7月10日，大约8.91万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300023992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","000650","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650294808","title":"仁和药业：目前只有ULOOK眼镜合作项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2650294808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650294808?lang=zh_cn&edition=full","pubTime":"2026-07-09 11:34","pubTimestamp":1783568064,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！贵公司与深圳必爱智能科技合作研发的产品有哪些？合作研发的产品各个研发进展如何？有哪些已经上市销售？仁和药业回复：尊敬的投资者您好：目前只有ULOOK眼镜合作项目。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900016889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649340689","title":"股市必读：仁和药业（000650）7月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649340689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649340689?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:33","pubTimestamp":1783449191,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，仁和药业报收于5.24元，下跌3.14%，换手率1.27%，成交量16.94万手，成交额8945.16万元。董秘最新回复投资者： 你好！请问,截止26年6月30号，公司股东人数是多少？2026年6月30日公司股东人数会在公司2026半年报里面披露，请您留意公司半年度报告。当日关注点交易信息汇总：7月7日主力资金净流出520.63万元，散户资金净流入550.9万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800001339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0239","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649616372","title":"股市必读：仁和药业（000650）7月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649616372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649616372?lang=zh_cn&edition=full","pubTime":"2026-07-06 01:41","pubTimestamp":1783273270,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，仁和药业报收于5.37元，上涨2.48%，换手率2.12%，成交量28.28万手，成交额1.51亿元。董秘最新回复投资者： 你好！公司公告汇总：截至2026年6月30日，仁和药业已累计回购16,740,050股，占总股本1.1958%，支付总金额94,847,116.56元，回购进展符合方案要求。交易信息汇总资金流向7月3日主力资金净流出2460.36万元，占总成交额0.0%；游资资金净流入869.63万元，占总成交额0.0%；散户资金净流入1590.73万元，占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600000575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","BK0239","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648525195","title":"股市必读：仁和药业（000650）7月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648525195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648525195?lang=zh_cn&edition=full","pubTime":"2026-07-02 04:02","pubTimestamp":1782936138,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，仁和药业报收于5.18元，上涨1.77%，换手率1.26%，成交量16.76万手，成交额8586.92万元。目前，证券部无应披露而未披露的信息。最新消息，国家医保局6月29日对通过2026年目录初审的药品名单和主要信息进行了公示，其中557个。交易信息汇总资金流向7月1日主力资金净流出425.4万元，占总成交额0.0%；游资资金净流出133.66万元，占总成交额0.0%；散户资金净流入559.05万元，占总成交额0.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200001899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648518382","title":"仁和药业：二冬汤颗粒在通过初步形式审查的目录外药品名单-基本目录（序号81）","url":"https://stock-news.laohu8.com/highlight/detail?id=2648518382","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648518382?lang=zh_cn&edition=full","pubTime":"2026-07-01 15:04","pubTimestamp":1782889459,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业07月01日在投资者关系平台上答复投资者关心的问题。最新消息，国家医保局6月29日对通过2026年目录初审的药品名单和主要信息进行了公示，其中557个。54个药品分别通过了基本医保药品目录、商保创新药目录初步形式审查，请问仁和药业有多少个药品通过了初步审查？另外，公司清肺汤颗粒在目录外预申报药品名单。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100023567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365578","title":"仁和药业（000650）披露2025年年度股东会决议公告，6月26日股价下跌2.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646365578?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:31","pubTimestamp":1782484273,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，仁和药业报收于4.99元，较前一交易日下跌2.73%，最新总市值为69.86亿元。该股当日开盘5.11元，最高5.15元，最低4.98元，成交额达8517.25万元，换手率为1.27%。近日，仁和药业发布《公司2025年年度股东会决议公告》。江西求正沃德律师事务所对本次会议出具法律意见书，认为会议表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646460843","title":"股市必读：仁和药业（000650）6月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2646460843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646460843?lang=zh_cn&edition=full","pubTime":"2026-06-25 03:48","pubTimestamp":1782330492,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘，仁和药业报收于5.18元，下跌1.71%，换手率0.98%，成交量13.01万手，成交额6807.29万元。董秘最新回复投资者： 董秘您好！江西省医保局在25年10月底发文，25年11月起正式落地执行五个脑机接口医疗服务价格项目 ，其中有一项非进入式脑机接口适配费每次 960元。目前，公司联合深圳必爱智能合作项目仍处于研发阶段，相关产品的最终功能定位、应用场景及商业化路径尚未最终确定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500003498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645934598","title":"仁和药业：引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2645934598","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645934598?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:21","pubTimestamp":1782289276,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！贵公司是否有意向引进外资而共同开发创新药吗？谢谢！仁和药业回复：尊敬的投资者，您好！引进外资共同开发创新药是当前中国医药产业从“跟随创新”向“源头创新”跃升的关键路径，已形成“资本+技术+市场”双向赋能的良性循环。公司持积极开放的态度。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400028909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0185","000650","BK0250","BK1574","BK0239","BK1161","BK0082","BK0175","BK0097","BK0010","159992","BK0028","BK0188","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645734700","title":"仁和药业（000650）披露全资子公司获得清肺汤颗粒药品注册证书的公告，6月22日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645734700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645734700?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:38","pubTimestamp":1782139099,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，仁和药业报收于5.15元，较前一交易日上涨0.39%，最新总市值为72.1亿元。该股当日开盘5.14元，最高5.23元，最低5.01元，成交额达7984.94万元，换手率为1.18%。仁和药业近日披露公告，其全资子公司江西药都樟树制药有限公司收到国家药监局核准签发的清肺汤颗粒《药品注册证书》，批准该药品上市。该品种为独家处方药，上市许可持有人为江西药都樟树制药有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200039055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095783","title":"每周股票复盘：仁和药业（000650）实控人变更为杨潇，奥司他韦获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095783","media":"证券之星","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095783?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:23","pubTimestamp":1781979789,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，仁和药业报收于5.13元，较上周的5.3元下跌3.21%。本周，仁和药业6月15日盘中最高价报5.35元。本周关注点公司公告汇总：实际控制人由杨文龙变更为杨潇，相关工商变更已完成。本次转让为间接控股股东的控制权变动，公司控股股东仍为仁和（集团）发展有限公司，实际控制人由杨文龙变更为杨潇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000650","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756721","title":"仁和药业（000650）披露子公司获得磷酸奥司他韦干混悬剂药品注册证书，6月16日股价下跌1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756721","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643756721?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:36","pubTimestamp":1781606162,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，仁和药业报收于5.26元，较前一交易日下跌1.31%，最新总市值为73.64亿元。近日，仁和药业子公司江西药都仁和制药有限公司收到国家药品监督管理局核准签发的磷酸奥司他韦干混悬剂《药品注册证书》，药品批准文号为国药准字H20264737，剂型为口服混悬剂，注册分类为化学药品3类。该药品适用于成人和2周龄及以上儿童的甲型与乙型流感治疗，以及1岁及以上人群的流感预防。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600035305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643731297","title":"仁和药业：已获批件的产品公司都有生产和销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2643731297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643731297?lang=zh_cn&edition=full","pubTime":"2026-06-16 15:06","pubTimestamp":1781593580,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！贵公司年报披露有35款新药取得批文，请问截止2026年5月31日，这35款新药中有几款上市销售？仁和药业回复：尊敬的投资者您好，公司2025年年度报告全文在研发投入部分披露了44个药品研发名称及进展情况等，截止今天，公司药品通过一致性评价和已获取药品注册证书的有17个。已获批件的产品，除了昨天刚刚披露的磷酸奥司他韦干混悬剂，其他已获批件的产品，公司都有生产和销售。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600020826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643578855","title":"股市必读：仁和药业（000650）6月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2643578855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643578855?lang=zh_cn&edition=full","pubTime":"2026-06-16 02:23","pubTimestamp":1781547790,"startTime":"0","endTime":"0","summary":"截至2026年6月15日收盘，仁和药业报收于5.33元，上涨0.57%，换手率0.95%，成交量12.62万手，成交额6700.63万元。关于实际控制人股权完成工商变更登记的公告2026年6月15日，仁和药业收到仁和（集团）发展有限公司通知，杨文龙先生向其子杨潇先生转让所持仁和（集团）发展有限公司73.1137%股权的工商变更登记手续已办理完毕。本次变更后，公司控股股东仍为仁和（集团）发展有限公司，实际控制人由杨文龙变更为杨潇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600001730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642259737","title":"仁和药业：截至2026年5月29日，大约9.02万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2642259737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642259737?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:36","pubTimestamp":1781235401,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问贵公司26年5月31日为止，股东人数为多少？谢谢！仁和药业回复：谢谢您的关注，截至2026年5月29日，大约9.02万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200014722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642461194","title":"仁和药业：截止2026年5月31号，公司的员工人数4805人","url":"https://stock-news.laohu8.com/highlight/detail?id=2642461194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642461194?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:03","pubTimestamp":1781078590,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问，截止26年5月31号公司的员工人数是多少？不是股东人数！谢谢。仁和药业回复：尊敬的投资者您好，截止2026年5月31号，公司的员工人数4805人。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000026218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0188","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642145986","title":"仁和药业：深圳三浦公司还需在原料、精准功效、技术壁垒和产品差异化等方面下苦功","url":"https://stock-news.laohu8.com/highlight/detail?id=2642145986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642145986?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:34","pubTimestamp":1780976080,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业06月09日在投资者关系平台上答复投资者关心的问题。受中国境内化妆品行业需求消费理性化、供给端监管政策及竞争同质化等因素影响，近年行业整体呈现增速明显放缓、结构分化、利润受压等特征。未来深圳三浦公司还需在原料、精准功效、技术壁垒和产品差异化等方面下苦功，强化研发。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900015152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0188","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640950621","title":"仁和药业（000650）披露股份回购进展公告，6月1日股价上涨1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640950621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640950621?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:24","pubTimestamp":1780323862,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，仁和药业报收于5.43元，较前一交易日上涨1.5%，最新总市值为76.02亿元。该股当日开盘5.37元，最高5.44元，最低5.31元，成交额达7880.15万元，换手率为1.1%。近日，仁和药业发布《关于股份回购进展情况的公告》。截至2026年5月31日，公司已累计回购股份16,360,050股，占公司总股本的1.1686%，最高成交价为5.73元/股，最低成交价为5.26元/股，支付总金额92,958,266.77元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100041095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","BK0239","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638552380","title":"股市必读：仁和药业（000650）5月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638552380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638552380?lang=zh_cn&edition=full","pubTime":"2026-05-26 02:49","pubTimestamp":1779734949,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，仁和药业报收于5.41元，上涨0.56%，换手率0.7%，成交量9.36万手，成交额5052.91万元。投资者： 你好，公司已经回购了多少股份董秘： 尊敬的投资者您好，公司于2026年5月13日披露，2026年回购股份已达14,000,650股。公司在2025年3月4日和12月1日，分别使用1000万进入公司证券账户，截至2025年12月31日，产生收益145.36万。依据公司2025年度审计报告，公司处置交易性金融资产取得的投资收益为156.9571万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600001881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","000650","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784253468411,"stockEarnings":[{"period":"1week","weight":0.0843},{"period":"1month","weight":0.076},{"period":"3month","weight":-0.0241},{"period":"6month","weight":-0.0706},{"period":"1year","weight":0.0018},{"period":"ytd","weight":0.0018}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0512},{"period":"3month","weight":-0.0417},{"period":"6month","weight":-0.0535},{"period":"1year","weight":0.1081},{"period":"ytd","weight":-0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"仁和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"89100人(较上一季度增加3.97%)","perCapita":"14942股","listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","registeredCapital":"139993万元","survey":" 仁和药业股份有限公司的主营业务是药品及大健康产品的生产和销售。公司的主要产品是口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂、健康相关产品。","listedPrice":6.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}